2 news items
Eye Drug Eylea Price Manipulation: Regeneron Faces US Justice Department Allegations Over Medicare Pricing Of Its Best-Selling Eye Drug
REGN
11 Apr 24
(NASDAQ:REGN), accusing the company of manipulating Medicare’s drug-pricing system for its macular
FDA Delays Decision For Regeneron's Inaugural Blood Cancer Therapy, Highlights Trial Concerns
REGN
25 Mar 24
: Median Drug Prices For Rare Diseases Hit $300K In 2023
- Prev
- 1
- Next